Your browser doesn't support javascript.
loading
Triglyceride-lowering LPL alleles combined with LDL-C-lowering alleles are associated with an additively improved lipoprotein profile.
Ibi, Dorina; Blauw, Lisanne L; Noordam, Raymond; Dollé, Martijn E T; Jukema, J Wouter; Rosendaal, Frits R; Christodoulides, Constantinos; Neville, Matt J; Koivula, Robert; Rensen, Patrick C N; Karpe, Fredrik; van Dijk, Ko Willems.
Afiliação
  • Ibi D; Dept. Human Genetics, Leiden University Medical Center, Leiden, the Netherlands; Dept. Public Health and Primary Care, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Electronic address: d.ibi@lumc.nl.
  • Blauw LL; Dept. Internal Medicine, Div. Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
  • Noordam R; Dept. Internal Medicine, Div. Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.
  • Dollé MET; Dept. Public Health and Primary Care, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Jukema JW; Dept. Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Rosendaal FR; Dept. Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Christodoulides C; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Neville MJ; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, United Kingdom.
  • Koivula R; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Rensen PCN; Dept. Internal Medicine, Div. Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
  • Karpe F; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford, United Kingdom.
  • van Dijk KW; Dept. Human Genetics, Leiden University Medical Center, Leiden, the Netherlands; Dept. Internal Medicine, Div. Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Atherosclerosis ; 328: 144-152, 2021 07.
Article em En | MEDLINE | ID: mdl-34053745
BACKGROUND AND AIMS: Mendelian randomization studies have shown that triglyceride (TG)- lowering lipoprotein lipase (LPL) alleles and low-density lipoprotein-cholesterol (LDL-C)-lowering alleles have independent beneficial associations on cardiovascular disease (CVD) risk. We aimed to provide further insight into this observation by applying Mendelian randomization analyses of genetically-influenced TG and LDL-C levels on plasma metabolomic profiles. METHODS: We quantified over 100 lipoprotein metabolomic measures in the Netherlands Epidemiology of Obesity (NEO) study (N = 4838) and Oxford Biobank (OBB) (N = 6999) by nuclear magnetic resonance (NMR) spectroscopy. Weighted genetic scores for TG via five LPL alleles and LDL-C via 19 alleles were calculated and dichotomized by the median, resulting in four genotype combinations of high/low TG and high/low LDL-C. We performed linear regression analyses using a two × two design with the group with genetically-influenced high TG and LDL-C as a reference. RESULTS: Compared to the individual groups with genetically-influenced lower TG or lower LDL-C only, the group with combined genetically-influenced lower TG and LDL-C showed an overall independent and additive pattern of changes in metabolomic measures. Over 100 measures were different (p < 1.35 × 10-3) compared to the reference, with effect sizes and directionality being similar in NEO and OBB. Most notably, levels of all very-low density lipoprotein (VLDL) and LDL sub-particles were lower. CONCLUSIONS: Our findings provide evidence that TG-lowering on top of LDL-C-lowering has additive beneficial effects on the lipoprotein profile compared to TG-lowering or LDL-C-lowering only, which is in accordance with reported additive genetic effects on CVD risk reduction.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lipase / Lipase Lipoproteica Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lipase / Lipase Lipoproteica Idioma: En Ano de publicação: 2021 Tipo de documento: Article